About: Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 21 May 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu en mayu de 2019 (ast) scientific article published on 21 May 2019 (en) наукова стаття, опублікована 21 травня 2019 (uk)
publication date	wds:Q92165468-F4E13B84-5F72-4BE1-9DED-EFBD6565A654
publication date	2019-05-21 00:00:00Z (xsd:dateTime)
cites work	wds:Q92165468-50427D15-1533-4323-90CF-5FAB3B99BAB2
cites work	A brief measure for assessing generalized anxiety disorder: the GAD-7.
author name string	wds:Q92165468-0479B22D-03AB-453B-A3E4-A62F4F4480E8 wds:Q92165468-06F6C3B6-BD75-461D-B03B-34D0F8918DE3 wds:Q92165468-14960C5D-91D1-4919-97A1-E46CCE111022 wds:Q92165468-1B72A3B9-EFFB-4195-8BE1-1D18D3CC5ABE wds:Q92165468-223634E4-4DEB-4C81-87CA-85C9805F7928 wds:Q92165468-246DF90D-2DE9-4FBD-9C3B-4692823D42ED wds:Q92165468-424CD539-26DD-4674-A428-6AFB595DCA0F wds:Q92165468-49FC6EEB-761A-48BD-9C02-DD087BFEA702 wds:Q92165468-52934E56-FF36-4EFD-8CE0-5F8B95E47963 wds:Q92165468-6B0F77AD-C776-4B02-9F8A-EC1FCA6DA2C6 wds:Q92165468-88AC1B31-E57E-4B65-A9E1-E6FDC870C9D1 wds:Q92165468-BB176392-91D2-4811-BEBA-106B5E6DE0DA wds:Q92165468-BFA32E0A-D7F2-4D00-BA4C-D1FA349FCCD3 wds:Q92165468-F680897D-A8E1-40EC-B0C1-11F6EA7DE36F
author name string	Michael E Thase Malek Bajbouj Kimberly Cooper David Hough Pilar Lim Rosanne Lane Wayne C Drevets Husseini Manji Richard C Shelton Madhukar Trivedi Vanina Popova Jaskaran B Singh Ella J Daly Christine Mazzucco
rdfs:label	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (en) Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (nl)
skos:prefLabel	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (en) Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (nl)
name	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (en) Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (nl)
author	wds:Q92165468-19E324F8-75CC-465C-9B5C-B3AED45E1237 wds:Q92165468-C223855C-7881-4577-863D-C07B7F96EEEA
author	Eduard Vieta Patricio Molero
title	wds:Q92165468-38CCF7C1-69FB-4F11-99D6-41AC2218D10F
title	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study (en)
page(s)	wds:Q92165468-03998DDF-13DA-44C4-B2D9-375DC5896E16
page(s)	428-438
instance of	wds:Q92165468-771FD4B0-57BB-4C17-BD31-6E89AA7A7CFD
instance of	scholarly article
main subject	wds:Q92165468-470960D5-28F2-4675-BEAE-D9890B02E9DB
main subject	treatment-resistant depression
PubMed ID	wds:Q92165468-D82D1F2B-07B8-4461-8E0F-B5783FEFC7C5
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31109201
PubMed ID	31109201
published in	wds:Q92165468-3D1B03B2-F3AB-425D-8A4F-999A1099DF13
published in	American Journal of Psychiatry
issue	wds:Q92165468-7FD2EC5A-6495-4414-847F-9B03E5525328
volume	wds:Q92165468-C8674C31-5B94-4E5F-B08D-0A49081C04BD
issue	6
volume	176
DOI	wds:Q92165468-56418767-808C-4586-8177-4C3DD60D0773
DOI	http://dx.doi.org/10.1176/APPI.AJP.2019.19020172
DOI	10.1176/APPI.AJP.2019.19020172
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q92165468
is cites work of	Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers Approval of esketamine for treatment-resistant depression Ketamine: Leading us into the future for development of antidepressants Mechanisms associated with the antidepressant-like effects of L-655,708 Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program Benefit-Risk Assessment of Esketamine Nasal Spray versus Placebo in Treatment-Resistant Depression Approval of esketamine for treatment-resistant depression - Authors' reply Esketamine for treatment resistant depression: a trick of smoke and mirrors? Esketamine clinical trials: reply to Maju et al Antidepressant efficacy and side effect burden: an updated guide for clinicians Genome-wide association study and polygenic risk score analysis of esketamine treatment response Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
is cites work of	wds:Q98513651-1E6188B3-ADD3-4E53-97F6-7C1DB938D5A3 wds:Q98386641-18D2A1D7-68FC-475D-97EB-B2FE1FBD86EC wds:Q95642618-AB7AF50D-20F5-4B20-B5A2-9E2AAC765CA9 wds:Q97598046-4E63FE27-EA1A-4D67-92E5-16B235C3DDBC wds:Q93020534-AC764F19-28A9-4FBF-9CDC-C6F251B8DF91 wds:Q98830300-83BF53AB-5C0B-4800-99A2-9695768295A3 wds:Q94451007-16F1AAFD-B9EF-438B-A3BE-8778BEBC262A wds:Q96304817-982481DC-B39D-42E8-BB08-8D05DA02AA22 wds:Q98158719-5C5E84FE-D1E4-42BD-A0EA-4453D02632AB wds:Q90012379-29D5D02B-46CA-4022-BF7F-A762866C28D4 wds:Q90631290-582D6938-7E72-4B92-9F31-8CF9FF6DE7FD wds:Q89842826-D0E0DE46-E416-47AA-84C1-0D03E499312B wds:Q91077725-32E0C6EB-BBCA-436F-A95A-ECC2EA7D7F50

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software